Accumetrics secures $7M in first round financing
Accumetrics has raised an additional $7 million in the first round of capital financing and has secured $24 million total in new capital.
The San Diego-based Accumetrics, a developer of the VerifyNow platelet testing system, said that this round of financing results are from its existing investors: Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Rivervest and Kaiser Permanente.
Accumetrics said that the financing will be used to complete the GRAVITAS trial and the CLIA waiver application for the VerifyNow P2Y12 test, which is under review by FDA, and is used to assess patient’s responses to antiplatelet therapy.
The San Diego-based Accumetrics, a developer of the VerifyNow platelet testing system, said that this round of financing results are from its existing investors: Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Rivervest and Kaiser Permanente.
Accumetrics said that the financing will be used to complete the GRAVITAS trial and the CLIA waiver application for the VerifyNow P2Y12 test, which is under review by FDA, and is used to assess patient’s responses to antiplatelet therapy.